// App-Quantinova.ai

BSH2020‐PO‐151 : Patient preferences for the treatment of paroxysmal nocturnal hemoglobinuria: results of a patient survey of ravulizumab (ALXN1210) and eculizumab in the UK

Researchers

Presenter

  • J. Devin Peipert

Principal Investigators

  • M. Griffin

  • A. Kulasekararaj

  • S. Yount

  • C. Martens

  • A. Sparling

  • K. A. Webster

  • D. Cella

  • I. Tomazos

  • M. Ogawa

  • J. Yu

  • A. Hill

  • K. Kaiser

Medical Centers

  • Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL

  • St James's institute of Oncology, Leeds

  • Department of Haematological Medicine,King’s College Hospital, NIHR/Wellcome King’s Clinical Research Facility,London,United Kingdom

  • Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL

  • Alexion Pharmaceuticals, Inc., Boston, MA, USA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

  • ALXN-1210

Outcome

  • N/A

Study Design

  • Randomized

  • Non Inferiority

Phase

  • III

Study Id's

  • NCT03056040

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved